Avalo Therapeutics(AVTX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Avalo Therapeutics
AVTX.US
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc.
1.813 T
AVTX.USMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
D
BiotechnologyIndustry
Industry Ranking227/386
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-88.76%E
    • Profit Margin-143627.12%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-86.62%E
    • Net Profit YoY-216.06%E
    • Total Assets YoY-27.89%E
    • Net Assets YoY-44.28%E
  • Cash ScoreD
    • Cash Flow Margin70.44%C
    • OCF YoY-86.62%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio31.60%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst

    Market Beat·
    US
    AVTX
    +1.67%
    US
    FBT
    +0.63%
    US
    IBBQ
    +0.65%
    Market Beat·
    US
    AVTX
    +1.67%
    US
    FBT
    +0.63%
    US
    IBBQ
    +0.65%

    Citizens Jmp Cuts Avalo Therapeutics (NASDAQ:AVTX) Price Target to $55.00

    Market Beat·
    US
    AVTX
    +1.67%
    US
    IBB
    +0.28%
    US
    ARKG
    +0.23%
    Market Beat·
    US
    AVTX
    +1.67%
    US
    IBB
    +0.28%
    US
    ARKG
    +0.23%

    These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results

    benzinga_article·
    US
    AVTX
    +1.67%
    US
    ARKG
    +0.23%
    US
    SBIO
    -0.98%
    benzinga_article·
    US
    AVTX
    +1.67%
    US
    ARKG
    +0.23%
    US
    SBIO
    -0.98%

    Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty

    Tip Ranks·
    US
    AVTX
    +1.67%
    US
    BIB
    +0.37%
    US
    ARKG
    +0.23%
    Tip Ranks·
    US
    AVTX
    +1.67%
    US
    BIB
    +0.37%
    US
    ARKG
    +0.23%

    Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.82, Implies 140% Upside

    TradingView·
    US
    AVTX
    +1.67%
    US
    XBI
    -0.39%
    US
    TMED
    +1.04%
    TradingView·
    US
    AVTX
    +1.67%
    US
    XBI
    -0.39%
    US
    TMED
    +1.04%
    © 2026 Longbridge｜Disclaimer